SCHEMBL3428602

SCHEMBL3428602

CC(C)(C)c1ccc(Cn2nc(C(=O)Nc3ccc(OC(F)(F)F)cc3)c3ccccc32)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.63
TP53 P04637 2/20 0.57
TRPV1 Q8NER1 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
RECQL P46063 1/20 0.49
EPHX2 P34913 1/20 0.49
NR1H4 Q96RI1 1/20 0.49
CACNA1H O95180 1/20 0.49
TNF P01375 1/20 0.47
NOD2 Q9HC29 1/20 0.47
NOD1 Q9Y239 1/20 0.47
MAPT P10636 1/20 0.47
CTNNB1 P35222 1/20 0.46
TCF7L2 Q9NQB0 1/20 0.46
CNR1 P21554 1/20 0.45
FSCN1 Q16658 1/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430292 0.90 PTGER4 (0.61) PTGER4SMN1; SMN2EPHX2NR1H4CACNA1H
SCHEMBL3428221 0.87 PTGER4 (0.61) PTGER4TP53SMN1; SMN2ALDH1A1GAA
SCHEMBL3430587 0.83 KMT2A (0.49) PTGER4GAAEPHX2NR1H4MAPT
SCHEMBL3428215 0.82 PTGER4 (0.63) PTGER4SMN1; SMN2CNR1FSCN1
SCHEMBL3428482 0.81 PTGER4 (0.61) PTGER4TP53SMN1; SMN2EPHX2TNF
SCHEMBL7151503 0.81 PTGER4 (0.60) PTGER4TP53SMN1; SMN2FSCN1
SCHEMBL3759797 0.81 TDP1 (0.48) PTGER4TP53SMN1; SMN2ALDH1A1GAA
SCHEMBL24273140 0.80 PTGER4 (0.74) PTGER4TP53SMN1; SMN2CACNA1H
SCHEMBL28361137 0.79 MAPT (0.58) PTGER4TP53TRPV1SMN1; SMN2EPHX2
SCHEMBL3430489 0.79 PTGER4 (0.47) PTGER4SMN1; SMN2MAPTCNR1FSCN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 PTGER4 3500/4885TP53 4767/4885TRPV1 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.